Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Torrent Pharmaceuticals Limited |
---|---|
Information provided by: | Torrent Pharmaceuticals Limited |
ClinicalTrials.gov Identifier: | NCT00939926 |
Objective:
Study Design:
Condition | Intervention | Phase |
---|---|---|
Healthy |
Drug: Risperidone |
Phase I |
Study Type: | Interventional |
Official Title: | Bioequivalence Study of Risperidone 1 mg Tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fed Conditions |
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Female Subjects:
Exclusion Criteria:
History or presence of significant:
Subjects who had:
Study ID Numbers: | 1120/07 |
Study First Received: | July 10, 2009 |
Last Updated: | July 15, 2009 |
ClinicalTrials.gov Identifier: | NCT00939926 History of Changes |
Health Authority: | United States: Institutional Review Board |
Neurotransmitter Agents Dopamine Tranquilizing Agents Malnutrition Psychotropic Drugs Risperidone |
Central Nervous System Depressants Dopamine Agents Healthy Antipsychotic Agents Serotonin |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Risperidone Psychotropic Drugs Central Nervous System Depressants Dopamine Antagonists |
Antipsychotic Agents Pharmacologic Actions Serotonin Antagonists Serotonin Agents Therapeutic Uses Dopamine Agents Central Nervous System Agents |